title: Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research.
abstract: Diffuse malignant peritoneal mesothelioma (DMPM) is an uncommon and locally aggressive tumor with poor prognosis. Currently, no standard therapy is available. The biology of this disease is still poorly understood. We performed a systematic search of relevant studies on clinical management and biological research of DMPM. Trials were selected using a predetermined protocol. The current evidence suggests that cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC) results in improved survival. Biological understanding of DMPM is currently evolving.
authors.affiliation: Department of Surgery, National Cancer Institute, Milan, Italy.
authors.forename: Dario
authors.initials: D
authors.lastname: Baratti
authors.forename: Shigeki
authors.initials: S
authors.lastname: Kusamura
authors.forename: Marcello
authors.initials: M
authors.lastname: Deraco
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion; D019941:Cyclin-Dependent Kinase Inhibitor p16; D066246:ErbB Receptors / Q000378:metabolism; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000378:metabolism; D008654:Mesothelioma / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D009363:Neoplasm Proteins / Q000378:metabolism; D010534:Peritoneal Neoplasms / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D017479:Receptors, Platelet-Derived Growth Factor / Q000378:metabolism; D000077022:Survivin; D019098:Telomerase / Q000032:analysis / Q000235:genetics
chemical_list: C107489:BIRC5 protein, human; C000614131:CDKN2A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D051034:Inhibitor of Apoptosis Proteins; D009363:Neoplasm Proteins; D000077022:Survivin; D066246:ErbB Receptors; D017479:Receptors, Platelet-Derived Growth Factor; D019098:Telomerase